SZLSF.US StageZero Life Sciences Ltd

Healthcare Biotechnology USA Stocks
0.0010 USD
Close of Oct 12, 2026
0.0005 0.0051
Market cap
USD 124K
P/E
-
P/B
5.60x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2024.

Is SZLSF.US undervalued?

Graham number

The Graham number of StageZero Life Sciences Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

StageZero Life Sciences Ltd fundamental analysis

No fundamental analysis for StageZero Life Sciences Ltd yet.

StageZero Life Sciences Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About StageZero Life Sciences Ltd

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-canc…

Full company profile